Antiphospholipid syndrome

Contraception and Pregnancy in Patients with Rheumatic Disease

Volumn , Issue , 2014, Pages 109-137

  Levine, Alana B ^a   Lockshin, Michael D ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929850132     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4939-0673-4_6     Document Type: Chapter

References (148)

1. Wasserman A, Neisser A, Bruck C. Eine Serodiagnostiche reaktion bei syphilis. Dtsch Med Wochenschr. 1906;32:745-9.
2. Pangborn MC, Pangborn, MC. A new seriologically active phospholipid from beef heart. Proc Soc Exp Biol Med. 1941;48:484-86.
3. Moore JE, Mohr CF. Biologically false positive serologic tests for syphilis; type, incidence, and cause. J Am Med Assoc. 1952;150:467-73.
4. Beaumont JL. Acquired hemorrhagic syndrome caused by a circulating anticoagulant; inhibition of the thromboplastic function of the blood platelets; description of a specifi c test. Sang. 1954;25:1-15.
5. Lechner K. A new type of coagulation inhibitor. Thromb Diath Haemorrh. 1969;21:482-99.
6. Soulier JP, Boffa MC. Avortements a repetition, thromboses et anticoagulant circulant antithromboplastine: trois observations. Nouv Presse Med. 1980;9:859-64.
7. Ernest JM, Marshburn PB, Kutteh WH. Obstetric antiphospholipid syndrome:An update on pathophysiology and management. Semin Reprod Med. 2012;29:522-39.
8. Branch DW, Dudley DJ, Mitchell MD, et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice:A model for autoimmune fetal loss. Am J Obstet Gynecol. 1990;163:210-6.
9. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci U S A. 1991;88:3069-73.
10. Bakimer R, Fishman P, Blank M, Sredni B, Djaldetti M, Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest. 1992;89:1558-63.
11. Out HJ, Kooijman CD, Bruinse HW, Derksen RH. Histopathological fi ndings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol. 1991;41:179-86.
12. De Wolf F, Carreras LO, Moerman P, Vermylen J, Van Assche A, Renaer M. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol. 1982;142: 829-34.
13. Ogishima D, Matsumoto T, Nakamura Y, Yoshida K, Kuwabara Y. Placental pathology in systemic lupus erythematosus with antiphospholipid antibodies. Pathol Int. 2000;50:224-9.
14. Rand JH, Wu XX, Andree HA, et al. Pregnancy loss in the antiphospholipid-antibody syndrome-a possible thrombogenic mechanism. N Engl J Med. 1997;337:154-60.
15. Rand JH, Wu XX, Quinn AS, Taatjes DJ. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus. 2010;19: 460-9.
16. Redecha P, Tilley R, Tencati M, et al. Tissue factor:A link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood. 2007;110:2423-31.
17. Holers VM, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med. 2002;195:211-20.
18. Salmon JE, Girardi G, Holers VM. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus. 2003;12:535-8.
19. Girardi G, Berman J, Redecha P, Spruce L, Thurman J, Kraus D, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003;112:1644-54.
20. Tincani A, Cavazzana I, Ziglioli T, Lojacono A, De Angelis V, Meroni P. Complement activation and pregnancy failure. Clin Rev Allergy Immunol. 2010;39:153-9.
21. Fishman P, Falach-Vaknine E, Zigelman R, Bakimer R, Djaldetti M, Shoenfeld Y. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest. 1993;91:1834-7.
22. Di Simone N, Raschi E, Testoni C, Castellani R, D'Asta M, Shi T, et al. Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro. Ann Rheum Dis. 2005;64:462-7.
23. Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D, Roumenia L, et al. Mutations in complement regulatory proteins predispose to preeclampsia:A genetic analysis of the PROMISSE cohort. PLoS Med. 2011;8:e1001013.
24. Giles I, Rahman A. How to manage patients with systemic lupus erythematosus who are also antiphospholipid antibody positive. Best Pract Res Clin Rheumatol. 2009;23:525-37.
25. Kutteh WH. Antiphospholipid antibodies and reproduction. J Reprod Immunol. 1997;35: 151-71.
26. Harris EN, Spinnato JA. Should anticardiolipin tests be performed in otherwise healthy pregnant women? Am J Obstet Gynecol. 1991;165:1272-7.
27. Infante-Rivard C, David M, Gauthier R, Rivard GE. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case-control study. N Engl J Med. 1991;325:1063-6.
28. Lockwood CJ, Romero R, Feinberg RF, Clyne LP, Coster B, Hobbins JC. The prevalence and biologic signifi cance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol. 1989;161:369-73.
29. Parke AL, Wilson D, Maier D. The prevalence of antiphospholipid antibodies in women with recurrent spontaneous abortion, women with successful pregnancies, and women who have never been pregnant. Arthritis Rheum. 1991;34:1231-5.
30. Petri M, Golbus M, Anderson R, Whiting-O'Keefe Q, Corash L, Hellmann D. Antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody in women with idiopathic habitual abortion. A controlled, prospective study of forty-four women. Arthritis Rheum. 1987;30: 601-6.
31. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfl ed Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1, 000 patients. Arthritis Rheum. 2002;46:1019-27.
32. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun. 2000;15: 145-51.
33. Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis. 2003;62:388-93.
34. Cervera R, Asherson RA, Acevedo ML, Gomez-Puerta JA, Espinosa G, De La Red G, et al. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis. 2004;63:1312-7.
35. Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum. 2002;31:256-63.
36. de Godoy MR P, Cacao JC, de Godoy JM P, Brandao AC, Silva Rossi Souza D. Chagas disease and anticardiolipin antibodies in older adults. Arch Gerontol Geriatr. 2005;41:235-8.
37. Mackworth-Young CG, Harris EN, Steere AC, Rizvi F, Malawista SE, Hughes GR, et al. Anticardiolipin antibodies in lyme disease. Arthritis Rheum. 1988;31:1052-6.
38. Munoz-Rodriguez FJ, Tassies D, Font J, Reverter JC, Cervera R, Sanchez-Tapias JM, et al. Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome. J Hepatol. 1999;30:770-3.
39. de Larranaga GF, Forastiero RR, Martinuzzo ME, Carreras LO, Tsariktsian G, Sturno MM, et al. High prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity. Lupus. 2000;9:594-600.
40. Sammaritano L. Hughes syndrome:Antiphospholipid syndrome. In: Khamashta M, editor. Hughes syndrome:Antiphospholipid syndrome. London: Springer; 2000. p. 144-54.
41. Gomez-Puerta JA, Cervera R, Espinosa G, Aguilo S, Bucciarelli S, Ramos-Casals M, et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum. 2006;35:322-32.
42. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classifi cation criteria for defi nite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309-11.
43. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classifi cation criteria for defi nite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
44. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientifi c and standardisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost. 2009;7:1737-40.
45. Erkan D, Derksen R, Levy R, Machin S, Ortel T, Pierangeli S, et al. Antiphospholipid syndrome clinical research task force report. Lupus. 2011;20:219-24.
46. Macklon NS, Geraedts JP, Fauser BC. Conception to ongoing pregnancy: the 'black box' of early pregnancy loss. Hum Reprod Update. 2002;8:333-43.
47. Chauleur C, Galanaud JP, Alonso S, Cochery-Nouvellon E, Balducchi JP, Mares P, et al. Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies. J Thromb Haemost. 2010;8: 699-706.
48. Geis W, Branch DW. Obstetric implications of antiphospholipid antibodies: pregnancy loss and other complications. Clin Obstet Gynecol. 2001;44:2-10.
49. Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy:A systematic review. Br J Haematol. 2006;132:171-96.
50. Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod. 1995;10:3301-4.
51. Roque H, Paidas MJ, Funai EF, Kuczynski E, Lockwood CJ. Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost. 2004;91:290-5.
52. Backos M, Rai R, Regan L. Antiphospholipid antibodies and infertility. Hum Fertil (Camb). 2002;5:30-4.
53. Rodesch F, Simon P, Donner C, Jauniaux E. Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obstet Gynecol. 1992;80:283-5.
54. Jaffe R. Investigation of abnormal fi rst-trimester gestations by color Doppler imaging. J Clin Ultrasound. 1993;21:521-6.
55. Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW. Antiphospholipid antibodies and fetal death. Obstet Gynecol. 1996;87:489-93.
56. Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease:A metaanalysis. J Rheumatol. 2006;33:2214-21.
57. The Stillbirth Collaborative Research Network Writing Group. Causes of death among stillbirths. JAMA. 2011;306(22):2459-68.
58. Lockshin MD, Kim M, Laskin CA, Guerra M, Branch MD, Merrill J, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum. 2012;64:2311-8.
59. Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GR. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol. 1996;14:131-6.
60. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome:An update of the Utah experience. Obstet Gynecol. 1992;80:614-20.
61. Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol. 1995;86: 555-9.
62. Polzin WJ, Kopelman JN, Robinson RD, Read JA, Brady K. The association of antiphospholipid antibodies with pregnancies complicated by fetal growth restriction. Obstet Gynecol. 1991;78:1108-11.
63. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;174:1584-9.
64. do Prado AD, Piovesan DM, Staub HL, Horta BL. Association of anticardiolipin antibodies with preeclampsia:A systematic review and meta-analysis. Obstet Gynecol. 2010;116: 1433-43.
65. Davey DA, MacGillivray I. The classifi cation and defi nition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol. 1988;158:892-8.
66. Heilmann L, Schorsch M, Hahn T, Fareed J. Antiphospholipid syndrome and pre-eclampsia. Semin Thromb Hemost. 2011;37:141-5.
67. Branch DW, Porter TF, Rittenhouse L, et al. Antiphospholipid antibodies in women at risk for preeclampsia. Am J Obstet Gynecol. 2001;184:825-32. discussion 32-4.
68. Clark EA, Silver RM, Branch DW. Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome? Curr Rheumatol Rep. 2007;9:219-25.
69. Dreyfus M, Hedelin G, Kutnahorsky R, Lehmann M, Viville B, Langer B, et al. Antiphospholipid antibodies and preeclampsia:A case-control study. Obstet Gynecol. 2001;97:29-34.
70. Le Thi TD, Tieulie N, Costedoat N, Andreu MR, Wechsler B, Vauthier-Brouzes D, et al. The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. Ann Rheum Dis. 2005;64:273-8.
71. Appenzeller S, Souza FH, Wagner Silva de Souza A, Shoenfeld Y, de Carvalho JF. HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies. Semin Arthritis Rheum. 2011;41:517-23.
72. Alsulyman OM, Castro MA, Zuckerman E, McGehee W, Goodwin TM. Preeclampsia and liver infarction in early pregnancy associated with the antiphospholipid syndrome. Obstet Gynecol. 1996;88:644-6.
73. Wada Y, Sakamaki Y, Kobayashi D, Ajiro J, Moro H, Murakami S, et al. HELLP syndrome, multiple liver infarctions, and intrauterine fetal death in a patient with systemic lupus erythematosus and antiphospholipid syndrome. Intern Med. 2009;48:1555-8.
74. Wang YQ, Niu JH, Wang JL, Ye RH, Zhao YY. Patient with antiphospholipid syndrome accompanied by pre-eclampsia who developed HELLP syndrome and eclampsia after abortion. Chin Med J (Engl). 2012;125:4142-4.
75. Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classifi cation criteria and treatment guidelines. Lupus. 2003;12:530-4.
76. Gomez-Puerta JA, Cervera R, Espinosa G, Bucciarelli S, Font J. Pregnancy and puerperium are high susceptibility periods for the development of catastrophic antiphospholipid syndrome. Autoimmun Rev. 2006;6:85-8.
77. Erkan D, Lockshin MD. Non-criteria manifestations of antiphospholipid syndrome. Lupus. 2010;19:424-7.
78. Tripodi A. Testing for lupus anticoagulants:All that a clinician should know. Lupus. 2009; 18:291-8.
79. Liestol S, Wisloff F. Effect of subcutaneous administration of dalteparin on lupus anticoagulant assays. Thromb Res. 2005;115:509-17.
80. Pengo V, Biasiolo A, Gresele P, et al. Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost. 2007;5:925-30.
81. Erkan D, Barbhaiya M, George D, Sammaritano L, Lockshin M. Moderate versus high-titer persistently anticardiolipin antibody positive patients:Are they clinically different and does high-titer anti-beta 2-glycoprotein-I antibody positivity offer additional predictive information? Lupus. 2010;19:613-9.
82. Ruffatti A, Tonello M, Visentin MS, et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies:A multicentre, case-control study. Rheumatology (Oxford). 2011;50:1684-9.
83. Ruffatti A, Calligaro A, Hoxha A, Trevisanuto D, Ruffatti AT, Gervasi MT, et al. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res (Hoboken). 2010;62:302-7.
84. Lockshin MD, Druzin ML, Goei S, Qamar T, Magid MS, Jovanovic L, et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med. 1985;313:152-6.
85. ACOG Practice Bulletin No. 118. Antiphospholipid syndrome. Obstet Gynecol. 2010;117: 192-9.
86. Fishman P, Falach-Vaknin E, Sredni B, Meroni PL, Rudniki C, Shoenfeld Y. Aspirin modulates interleukin-3 production:Additional explanation for the preventive effects of aspirin in antiphospholipid antibody syndrome. J Rheumatol. 1995;22:1086-90.
87. Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol. 2000;183:1008-12.
88. Salmon JE, Girardi G, Lockshin MD. The antiphospholipid syndrome as a disorder initiated by infl ammation: implications for the therapy of pregnant patients. Nat Clin Pract Rheumatol. 2007;3:140-7. quiz 1 p following 87.
89. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005;18(2): CD002859.
90. Empson M, Lassere M, Craig JC, Scott JR. Recurrent pregnancy loss with antiphospholipid antibody:A systematic review of therapeutic trials. Obstet Gynecol. 2002;99:135-44.
91. Mak A, Cheung MW, Cheak AA, Ho RC. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies:A meta-analysis of randomized controlled trials and metaregression. Rheumatology (Oxford). 2010;49:281-8.
92. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314:253-7.
93. Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss:A systematic review and meta-analysis. Obstet Gynecol. 2010;115: 1256-62.
94. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy:A randomized, controlled trial of treatment. Obstet Gynecol. 2002;100:408-13.
95. Laskin CA, Spitzer KA, Clark CA, Crowther MR, Ginsberg JS, Hawker GA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol. 2009;36:279-87.
96. Noble LS, Kutteh WH, Lashey N, Franklin RD, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril. 2005;83:684-90.
97. Stephenson MD, Ballem PJ, Tsang P, Purloss S, Ensworth S, Houlihan E, et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy:A randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can. 2004;26: 729-34.
98. Johnson R, Charnley J. Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty. Clin Orthop Relat Res. 1979;144:174-7.
99. Wallace DJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum. 1987;30:1435-6.
100. Petri M. Hydroxychloroquine use in the Baltimore lupus cohort: effects on lipids, glucose and thrombosis. Lupus. 1996;5 Suppl 1:S16-22.
101. Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis. 2009;68: 238-41.
102. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Martinez-Berriotxoa A, Erdozain JG, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15:577-83.
103. Levy RA, Vilela VS, Cataldo MJ, Ramos RC, Duarte JL, Tura BR, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001;10: 401-4.
104. Triolo G, Ferrante A, Ciccia F, Accardo-Palumbo A, Perino A, Castelli A, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum. 2003;48:728-31.
105. Dendrinos S, Sakkas E, Makrakis E. Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome. Int J Gynaecol Obstet. 2009;104:223-5.
106. Branch DW, Peaceman AM, Druzin M, Silver RK, El-Sayed Y, Silver RM, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The pregnancy loss study group. Am J Obstet Gynecol. 2000;182:122-7.
107. Spinnato JA, Clark AL, Pierangeli SS, Harris EN. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am J Obstet Gynecol. 1995;172:690-4.
108. Triolo G, Ferrante A, Accardo-Palumbo A, Ciccia F, Cadelo M, Castelli A, et al. IVIG in APS pregnancy. Lupus. 2004;13:731-5.
109. Frampton G, Cameron JS, Thom M, Jones S, Raftery M. Successful removal of antiphospholipid antibody during pregnancy using plasma exchange and low-dose prednisolone. Lancet. 1987;2:1023-4.
110. Fulcher D, Stewart G, Exner T, Trudinger B, Jeremy R. Plasma exchange and the anticardiolipin syndrome in pregnancy. Lancet. 1989;2:171.
111. Bortolati M, Marson P, Chiarelli S, Tison T, Facchinetti M, Gervasi MT, et al. Case reports of the use of immunoadsorption or plasma exchange in high-risk pregnancies of women with antiphospholipid syndrome. Ther Apher Dial. 2009;13:157-60.
112. El-Haieg DO, Zanati MF, El-Foual FM. Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome. Int J Gynaecol Obstet. 2007;99:236-41.
113. Ruffatti A, Marson P, Pengo V, Favaro M, Tonello M, Bortolati M, et al. Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun Rev. 2007;6:196-202.
114. Bramham K, Thomas M, Nelson-Piercy C, Khamashta M, Hunt BJ. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood. 2011;117:6948-51.
115. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies:A collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol. 1992;166:1318-23.
116. Laskin CA, Bombardier C, Hannah ME, Mandel FP, Ritchie JW, Farewell V, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med. 1997;337:148-53.
117. Lockshin MD, Druzin ML, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol. 1989;160:439-43.
118. Silver RK, MacGregor SN, Sholl JS, Hobart JM, Neerhof MG, Ragin A. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibodypositive obstetric patients. Am J Obstet Gynecol. 1993;169:1411-7.
119. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy:Antithrombotic therapy and prevention of thrombosis, 9th ed:American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e691S-736.
120. Practice Bulletin No. 132. Antiphospholipid syndrome. Obstet Gynecol. 2012;120:1514-21.
121. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest. 2001;119:122S-31.
122. Levy RA, Jesus GR, Jesus NR. Obstetric antiphospholipid syndrome: still a challenge. Lupus. 2010;19:457-9.
123. Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol. 2008;112:359-72.
124. de Jesus GR, dos Santos FC, Oliveira CS, Mendes-Silva W, de Jesus NR, Levy RA. Management of obstetric antiphospholipid syndrome. Curr Rheumatol Rep. 2012;14:79-86.
125. Le Thi HD, Wechsler B, Vauthier-Brouzes D, Duhaut P, Costedoat N, Andreu MR, et al. The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome. Rheumatology (Oxford). 2006;45:332-8.
126. Branch W. Report of the obstetric APS task force: 13th international congress on antiphospholipid antibodies, 13th April 2010. Lupus. 2011;20:158-64.
127. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy:American College of chest physicians evidencebased clinical practice guidelines (8th edition). Chest. 2008;133:844S-86.
128. Temprano KK, Bandlamudi R, Moore TL. Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum. 2005;35:112-21.
129. Sammaritano LR. Therapy insight: guidelines for selection of contraception in women with rheumatic diseases. Nat Clin Pract Rheumatol. 2007;3:273-81. quiz 305-6.
130. Botet F, Romera G, Montagut P, Figueras J, Carmona F, Balasch J. Neonatal outcome in women treated for the antiphospholipid syndrome during pregnancy. J Perinat Med. 1997;25: 192-6.
131. Ruffatti A, Dalla Barba B, Del Ross T, Vettorato F, Rapizzi E, Tonello M, et al. Outcome of fi fty-fi ve newborns of antiphospholipid antibody-positive mothers treated with calcium heparin during pregnancy. Clin Exp Rheumatol. 1998;16:605-10.
132. Brewster JA, Shaw NJ, Farquharson RG. Neonatal and pediatric outcome of infants born to mothers with antiphospholipid syndrome. J Perinat Med. 1999;27:183-7.
133. Tincani A, Lojacono A, Taglietti M, Motta M, Biasini C, Decca L, et al. Pregnancy and neonatal outcome in primary antiphospholipid syndrome. Lupus. 2002;11:649.
134. Boffa MC, Aurousseau MH, Lachassinne E, Dauphin H, Fain O, Le Toumelin P, et al. European register of babies born to mothers with antiphospholipid syndrome. Lupus. 2004;13:713-7.
135. Boffa MC, Lachassinne E. Infant perinatal thrombosis and antiphospholipid antibodies:A review. Lupus. 2007;16:634-41.
136. Hornstein MD. Antiphospholipid antibodies in patients undergoing IVF: the data do not support testing. Fertil Steril. 2000;74:635-6.
137. Hatasaka H, Porter TF, Silver RM, Lee RM, Ricks C, Branch DW. Antiphospholipid antibody levels are not elevated among women with tubal factor and unexplained infertility. Annu Proc Am Soc Reprod Med. 1997;68:S18.
138. Hornstein MD, Davis OK, Massey JB, Paulson RJ, Collins JA. Antiphospholipid antibodies and in vitro fertilization success:A meta-analysis. Fertil Steril. 2000;73:330-3.
139. Denis AL, Guido M, Adler RD, Bergh PA, Brenner C, Scott Jr RT. Antiphospholipid antibodies and pregnancy rates and outcome in in vitro fertilization patients. Fertil Steril. 1997;67: 1084-90.
140. Chilcott IT, Margara R, Cohen H, Rai R, Skull J, Pickering W, et al. Pregnancy outcome is not affected by antiphospholipid antibody status in women referred for in vitro fertilization. Fertil Steril. 2000;73:526-30.
141. Steinvil A, Raz R, Berliner S, Steinberg DM, Zeltser D, Levran D, et al. Association of common thrombophilias and antiphospholipid antibodies with success rate of in vitro fertilisation. Thromb Haemost. 2012;108:1192-7.
142. Medicine PCoASfR. Anti-phospholipid antibodies do not affect IVF success. Fertil Steril. 2008;90:S172-3.
143. Guballa N, Sammaritano L, Schwartzman S, Buyon J, Lockshin MD. Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum. 2000;43:550-6.
144. Le Thi HD, Wechsler B, Piette JC. Ovulation induction therapy and systemic lupus erythematosus. Ann Med Interne (Paris). 2003;154:45-50.
145. Udoff LC, Branch DW. Management of patients with antiphospholipid antibodies undergoing in vitro fertilization. J Autoimmun. 2000;15:209-11.
146. Bellver J, Pellicer A. Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome. Fertil Steril. 2009;92:1803-10.
147. Gray JC, Bouvier S, Molinari N, Galanaud JP, Nouvellon-E C, Mercier E, et al. Comparative incidence of a fi rst thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood. 2011;119:2624-32.
148. Martinez-Zamora MA, Peralta S, Creus M, Tassies D, Reverter JC, Espinosa G, et al. Risk of thromboembolic events after recurrent spontaneous abortion in antiphospholipid syndrome:A case-control study. Ann Rheum Dis. 2012;71:61-6.